Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Fierce Pharma

JUNE 29, 2023

Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking t | Half a decade after Abcam quit its £270 million pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the (..)

Antibody 85

Antibody Sales Research 85

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

Fierce Pharma

AUGUST 28, 2023

It’s a sale. Two months after Abcam launched a strategic review of the company, the British antibody research expert has revealed that it’s being bought by Danaher. Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday.

Antibody 98

Antibody Sales Research 98

Drug Discovery World

SEPTEMBER 12, 2023

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono.

Antibody 72

Antibody Sales Production Development 72

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

BioTech 365

JUNE 30, 2021

XBiotech Announces Receipt of $75 Million from Sale of Antibody XBiotech Announces Receipt of $75 Million from Sale of Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody AUSTIN, Texas, June 30, … Continue reading →

Sales 40

Sales Antibody 40

BioSpace

OCTOBER 26, 2023

billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3

Sales 120

Sales Antibody Drugs 120

Roots Analysis

FEBRUARY 27, 2024

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. Check the details of the agreement here.

Antibody 40

Antibody Marketing Drugs Contract Manufacturing 40

Drug Discovery World

SEPTEMBER 6, 2023

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature. In 2022, there were 156 antibody-focused deals with a value of $57.3 Reference [link] The post Antibody development drives high-value biotech deals appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Sales Manufacturing 52

pharmaphorum

OCTOBER 6, 2022

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4

Sales 97

Sales Drugs Branding Antibody 97

Fierce Pharma

MARCH 7, 2024

GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.

Antibody 108

Antibody Sales Trials Medicine 108

Bio Pharma Dive

MAY 4, 2022

revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.

Sales 152

Sales Antibody Drugs Marketing 152

Drug Discovery World

JANUARY 11, 2023

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . The post Collaboration to identify up to 10 novel target-antibody pairs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Engineer Immune Response Sales 52

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.

Sales 103

Sales Production Vaccination Vaccine 103

pharmaphorum

FEBRUARY 8, 2022

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. Pfizer shares actually fell in the wake of its results announcement as some analysts had been forecasting higher sales for Comirnaty this year.

Sales 98

Sales Vaccination Vaccine Antibody 98

XTalks

SEPTEMBER 7, 2021

After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant. 1 and Beta/B.1.351, 1.351, respectively). “The

Antibody 97

Antibody In-Vitro Drugs Sales 97

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Sales 124

pharmaphorum

AUGUST 6, 2021

billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2

Sales 105

Sales Vaccination Vaccine Antibody 105

Drug Discovery World

OCTOBER 21, 2022

billion, plus royalties on net sales. Zanidatamab is a HER2-targeted bispecific antibody with novel mechanisms of action. The post Jazz acquires rights to HER2-targeted bispecific antibody appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Licensing Licensing Sales 52

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda.

Drugs 264

Drugs Sales Antibody Dermatology 264

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

Roots Analysis

OCTOBER 25, 2023

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72

Antibody 40

Antibody Development Drugs Marketing 40

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.

Sales 91

Sales Vaccination Vaccine Drugs 91

Pharmaceutical Technology

MAY 5, 2023

In the US, Eylea’s (aflibercept) net product sales decreased by 6% to $1.43bn from $1.5bn in Q1 2022 owing to a rise in sales-related deductions, partly offset by higher sales volume. Worldwide net sales of Dupixent increased by 37% to $2.49bn Q1 to Q1 2022-23. “We

Sales 130

Sales Antibody Production Medicine 130

pharmaphorum

OCTOBER 18, 2022

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7

Antibody 52

Antibody Sales Clinical Trials Clinical Trials 52

Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Development 130

Development Antibody Pharma Production Engineer 130

pharmaphorum

NOVEMBER 17, 2021

The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion. The post US signs $1bn order for GSK, Vir’s COVID-19 antibody appeared first on. Another phase 3 trial called COMET-STAR is assessing whether.

Antibody 52

Antibody Sales Regulation Trials 52

Fierce Pharma

MARCH 7, 2024

Despite weathering a host of launch challenges with Leqembi, Eisai still has big hopes for its amyloid-busting antibody in early Alzheimer’s disease. | Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 89

Sales Antibody Drugs 89

Pharmaceutical Technology

FEBRUARY 14, 2023

HBM7008 has been developed from HBICE, a next-generation heavy chain-only antibody (HCAb)-based multi-specific antibody discovery platform. CLN-418 is a strong strategic fit for Cullinan, building on our expertise with bispecifics and placing us at the forefront of bispecific antibody development in solid tumours.”

Antibody 130

Antibody Sales Clinical Trials Clinical Trials 130

Fierce Pharma

JANUARY 9, 2024

The rise of hemophilia A blockbuster Hemlibra and antibody-drug conjugate Polivy have helped stem the tide. Newer T-cell engagers Lunsumio and Columvi, both approved over the last 14 months, will continue to fuel the turnaround, Roche said Tuesday at the J.P. Morgan Healthcare Conference.

Sales 91

Sales Antibody Drugs 91

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Vaccination 272

Vaccination Vaccine Sales Generic Drugs 272

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. BB-1701 comprises anti-HER2 antibody and eribulin and has a unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

FEBRUARY 8, 2023

Despite receding sales, Comirnaty, its partnered COVID-19 vaccine with BioNTech, is still forecast to reach the analyst consensus global forecast sales of $33 billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. billion on Dec 31, 2022. Merck & Co. billion to $281.3 and 31.6%, respectively.

Marketing 195

Marketing Sales Vaccination Vaccine 195